Subcutaneous IL-6 Inhibitor Sarilumab vs. Standard Care in Hospitalized Patients With Moderate-To-Severe COVID-19: An Open Label Randomized Clinical Trial

Subcutaneous IL-6 Inhibitor Sarilumab vs. Standard Care in Hospitalized Patients With Moderate-To-Severe COVID-19: An Open Label Randomized Clinical Trial

BackgroundThe use of IL-6 blockers in COVID-19 hospitalized patients has been associated with a reduction in mortality compared to standard care. However, many uncertainties remain pertaining to optimal intervention time, administration schedule, and predictors of response. To date, data on the use...

Full description

Bibliographic Details
Main Authors: Rosario García-Vicuña, Sebastián C. Rodriguez-García, Francisco Abad-Santos, Azucena Bautista Hernández, Lucio García-Fraile, Ana Barrios Blandino, Angela Gutiérrez Liarte, Tamara Alonso-Pérez, Laura Cardeñoso, Aránzazu Alfranca, Gina Mejía-Abril, Jesús Sanz Sanz, Isidoro González-Alvaro
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-02-01
Series:Frontiers in Medicine
Subjects:
COVID-19
sarilumab
subcutaneous route
IL-6
IL-6 receptor inhibitors
IL-6 blockade
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.819621/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.819621/full

Similar Items